Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vofatamab alone or with docetaxel in advanced urothelial cell carcinoma
NCT02401542Phase 2Terminated
- Sponsor
- Rainier Therapeutics
- Start
- Jun 2015
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of vofatamab in urothelial carcinoma (UC), sponsored by Rainier Therapeutics. Started Jun 2015; status: terminated.
02
Drugs
vofatamab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02401542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401542.